RE:New Press Release - PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS IsraelI like the good will of PharmAla to step in and step up to provide the needed pills for MDMA-assisted therapy in an area of the world that is seeing so much trauma. It's good Karma. For a junior company on the stock exchange to do this is pretty much unheard of. I know it is not without benefits to the company itself with their rights to the data collected in exchange for the pills, but it's nice to be invested in a company that seems to genuinely care about what they do and how they can help others. Hopefully that also translates into a great investment, as Nick still has a responsibility to his shareholders. Time will tell if all those involved with PharmAla in one way or the other (i.e. investor, company, client or patient) will prosper from the benefits of MDMA-assisted therapy and Pharmala's IP's. Perhaps the ability to start providing pills for free in certain circumstances may suggest that financially the company is at the point of profitability. We will see very soon. A possible win-win for all!